Compare Tango Therapeutics Inc. (TNGX) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs Wheaton Precious Metals Corp — how do they compare? Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B), while Wheaton Precious Metals Corp trades at $132.53 (market cap $61.55B). The key difference: Wheaton Precious Metals Corp is far larger — about 16.4× Tango Therapeutics Inc.'s market cap, and Wheaton Precious Metals Corp pays a 0.57% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and Wheaton Precious Metals Corp for 66 Days on average.
| TNGX | WPM | |
|---|---|---|
Market Cap | $3.75B | $61.55B |
Volume | 9,619,106 | 932,802 |
Sector | Health | Basic Materials |
52-Week High | $32.90 | $165.72 |
52-Week Low | $7.50 | $94.37 |
Typical Hold Time | 0 Days | 66 Days |
Enterprise Value | $2.77B | $63.43B |
Dividend Yield | — | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Wheaton Precious Metals (WPM) trades at $129.58, down 6.18% over 24 hours, with a bullish technical signal from moving averages but neutral oscillators. The company reported record 2025 revenue of $2.31 billion and net income of $1.47 billion, with earnings beating estimates in recent quarters. Management targets 50% production growth by 2030 without new capital, supported by a strong deal pipeline.
WPM presents a growth opportunity with high profitability margins and analyst consensus favoring a buy rating, but faces risks from gold price volatility and execution of expansion plans. The stock's valuation multiples are elevated, requiring sustained earnings growth to justify current levels amid macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
